Cross-platform analysis of HIV-1 RNA data generated by a multicenter assay validation study with wide geographic representation.

dc.contributor.author

Jennings, Cheryl

dc.contributor.author

Harty, Brian

dc.contributor.author

Granger, Suzanne

dc.contributor.author

Wager, Carrie

dc.contributor.author

Crump, John A

dc.contributor.author

Fiscus, Susan A

dc.contributor.author

Bremer, James W

dc.coverage.spatial

United States

dc.date.accessioned

2017-03-02T19:16:38Z

dc.date.available

2017-03-02T19:16:38Z

dc.date.issued

2012-08

dc.description.abstract

HIV-1 RNA quantitation continues to be extremely important for monitoring patients infected with HIV-1, and a number of assays have been utilized for this purpose. Differences in assay performance with respect to log(10) recovery and HIV-1 subtype specificity have been well documented for commercially available assays, although comparisons are usually limited to one or two assay platforms. Two new FDA-approved assays, the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test (RT) and the Abbott RealTime HIV-1 assay (AR), that utilize real-time PCR have replaced previous HIV-1 RNA platforms. Inadequate detection of some strains of HIV-1 resulted in the addition of a new primer/probe set and the introduction of a second version of the RT assay. In this study, comparisons of assay performance between the different FDA-approved HIV-1 RNA assay platforms (both new and existing) were performed by using validation data that included both well-characterized virus stock and locally collected clinical samples. Laboratories across diverse geographical regions performed the validation testing and submitted data to the Virology Quality Assurance program (VQA) for analysis. Correlation values for clinical sample testing varied across the assay platforms (r = 0.832 to 0.986), and average log(10) recoveries for HIV-1 RNA controls (compared to the nominal value) ranged from -0.215 to 0.181. These data demonstrate the need for use of one assay platform for longitudinal patient monitoring, but the data also reinforce the notion that no one assay is superior and that testing across platforms may be required for discordance reconciliation.

dc.identifier

https://www.ncbi.nlm.nih.gov/pubmed/22692747

dc.identifier

JCM.00578-12

dc.identifier.eissn

1098-660X

dc.identifier.uri

https://hdl.handle.net/10161/13784

dc.language

eng

dc.publisher

American Society for Microbiology

dc.relation.ispartof

J Clin Microbiol

dc.relation.isversionof

10.1128/JCM.00578-12

dc.subject

HIV Infections

dc.subject

HIV-1

dc.subject

Humans

dc.subject

Quality Assurance, Health Care

dc.subject

RNA, Viral

dc.subject

Real-Time Polymerase Chain Reaction

dc.subject

Viral Load

dc.title

Cross-platform analysis of HIV-1 RNA data generated by a multicenter assay validation study with wide geographic representation.

dc.type

Journal article

pubs.author-url

https://www.ncbi.nlm.nih.gov/pubmed/22692747

pubs.begin-page

2737

pubs.end-page

2747

pubs.issue

8

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, Infectious Diseases

pubs.organisational-group

Pathology

pubs.organisational-group

School of Medicine

pubs.publication-status

Published

pubs.volume

50

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
JClinMicrobiol_HIVRNACrossPlatform.pdf
Size:
1.59 MB
Format:
Adobe Portable Document Format